Individuals who are hospitalized for the skin conditions of Stevens-Johnson syndrome and toxic epidermal necrolysis appear to have a high risk of recurrence, according to a new study.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening conditions that develop primarily as responses to drugs, and result in extensive epidermal detachment (upper layers of the skin detach from the lower layers). Recurrence has been reported in isolated cases, and the overall risk of recurrence has been unknown, according to background information in the article.
Yaron Finkelstein, M.D., of the Hospital for Sick Children, Toronto, and colleagues conducted a study that included data of all Ontario residents hospitalized for a first episode of Stevens-Johnson syndrome or toxic epidermal necrolysis between April 2002 and March 2011. Patients were followed up from admission until March 31, 2012, or death. The researchers identified 708 individuals hospitalized for a first episode of SJS (n = 567) or TEN (n = 141), including 127 (17.9 percent) children younger than 18 years.
Forty-two patients (7.2 percent) were hospitalized for a subsequent episode of Stevens-Johnson syndrome or toxic epidermal necrolysis. Eight patients (1.4 percent) experienced multiple recurrences. The median time to first recurrence was 315 days.
“In light of the reported incidence of SJS and TEN in the general population (1.0-7.2 cases/1 million individuals/year), the observed recurrence risk in our study (>7 percent) is several thousand-fold higher than would be expected if subsequent episodes were probabilistically independent of the first SJS or TEN episode. We speculate that this increased risk reflects individual susceptibility. Genetic predisposition has been identified for several medications in association with specific genotypes …” the authors write.
“… these findings are relevant to physicians who care for patients with a history of SJS or TEN. Because most such episodes are drug-induced, the high risk of recurrence should be recognized, and the benefits of drug therapy weighed carefully against the potential risks. This is particularly true for drugs commonly associated with the development of these frequently fatal conditions.”
Citation: Yaron Finkelstein MD, ABCP(Dip), Erin M. Macdonald MSc, Ping Li PhD, Janine R. Hutson MD, MSc, David N. Juurlink MD, PhD, 'Recurrence and Mortality Following Severe Cutaneous Adverse Reactions', JAMA. 2014;311(21):2231-2232. doi:10.1001/jama.2014.839
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- The Plot Of The Week: CMS Search For Majorana Neutrinos
- Football Physics: The Science Of Deflategate
- Reviews In Physics - A New Journal
- We're Playing Classical Music All Wrong
- Think Mosquitoes Bite You More Than Other People? Here's Why You May Be Right
- Happy 150th Birthday To Maxwell's Theory Of Electromagnetism
- Promonitor Index: 5 Key Ways To Assess Reef Health
- "Do I hear a note of lamentation in the followings?Lamenting the fact that countries they thought..."
- "Robert:Perhaps a simple expression of their stance may be summed up as: Nothing is really..."
- "Yes, thanks, that answers my question. And I agree with the error bars. Even if no quantitative..."
- "Is it possible that the leather cover of the football, after being prepared by the teams (assume..."
- "Catholics were first. Perhaps you mean Holy Roman Catholic, but the first Christian prayer says..."
- Brain study sheds light on how children with autism process social play
- Not just language: Cochlear implant users can hear and feel the beat in music too
- The weather forecast for today is partly wrong with a chance of being right
- Pain from shots shows up in infant brain activity too
- Study identifies geographic long-term clusters of anti-vaccine beliefs in Northern California